$INNV Innovus Pharmaceuticals Reports Preliminary
Post# of 405
(Total Views: 390)
Posted On: 07/17/2018 7:58:39 AM
$INNV Innovus Pharmaceuticals Reports Preliminary Q2 2018 Sales Revenue of $6.6 million to $6.8 millionPress Release | 07/17/2018
Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (OTCQB: INNV), today announced preliminary second quarter 2018 net revenue is estimated to be between $6.6 million to $6.8 million or an approximate 47-51% increase from the first quarter of 2018 and an approximate increase of 330-340% from the second quarter of 2017. Innovus Pharma's second quarter 2018 anticipated revenue results are preliminary and based on the most current information available and are subject to completion of the condensed consolidated financial statements for the second quarter of 2018, which are to be filed with the SEC no later than August 14, 2018.
“We are seeing exceptional growth in our sales channels, additional markets and product pipeline which now stands at 32 products in the United States and overall net revenue growth during 2018 with our estimated second quarter net revenue of between $6.6 million to $6.8 million. Because of our continued strong growth, we have adjusted our 2018 annual revenue guidance from $18 million to at least $22 million. We believe our revenue growth into 2018 highlights the continued strength of our ability to sell multiple products and increase the sales channels through our Beyond Human™ sales and marketing platform, direct mailing, e-commerce sites and other sales channels,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “We also continue to work hard towards our goal of profitability.”
Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (OTCQB: INNV), today announced preliminary second quarter 2018 net revenue is estimated to be between $6.6 million to $6.8 million or an approximate 47-51% increase from the first quarter of 2018 and an approximate increase of 330-340% from the second quarter of 2017. Innovus Pharma's second quarter 2018 anticipated revenue results are preliminary and based on the most current information available and are subject to completion of the condensed consolidated financial statements for the second quarter of 2018, which are to be filed with the SEC no later than August 14, 2018.
“We are seeing exceptional growth in our sales channels, additional markets and product pipeline which now stands at 32 products in the United States and overall net revenue growth during 2018 with our estimated second quarter net revenue of between $6.6 million to $6.8 million. Because of our continued strong growth, we have adjusted our 2018 annual revenue guidance from $18 million to at least $22 million. We believe our revenue growth into 2018 highlights the continued strength of our ability to sell multiple products and increase the sales channels through our Beyond Human™ sales and marketing platform, direct mailing, e-commerce sites and other sales channels,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “We also continue to work hard towards our goal of profitability.”
(0)
(0)